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Histonedeacetylaseinhibitors(HDACi)aresmallmoleculesthathaveimportantandpleiotropiceﬀectsoncellhomeostasis.Under
distinct developmental conditions, they can promote either self-renewal or diﬀerentiation of embryonic stem cells. In addition,
they can promote directed diﬀerentiation of embryonic and tissue-speciﬁc stem cells along the neuronal, cardiomyocytic, and
hepatic lineages. They have been used to facilitate embryo development following somatic cell nuclear transfer and induced pluri-
potent stem cell derivation by ectopic expression of pluripotency factors. In the latter method, these molecules not only increase
eﬀectiveness, but can also render the induction independent of the oncogenes c-Myc and Klf4. Here we review the molecular
pathways that are involved in the functions of HDAC inhibitors on stem cell diﬀerentiation and reprogramming of somatic cells
into pluripotency. Deciphering the mechanisms of HDAC inhibitor actions is very important to enable their exploitation for
eﬃcient and simple tissue regeneration therapies.
1.Introduction
Stem cells are distinguished from other cell types by their
unique properties to self-renew and diﬀerentiate along mul-
tiple lineages [1]. These processes are regulated by extrinsic
and intrinsic determinants that aﬀect gene expression pro-
ﬁles, signal transduction pathways, and epigenetic mecha-
nisms.
DNA methylation and histone modiﬁcations constitute
major mechanisms that are responsible for epigenetic regu-
lation of gene expression during development and diﬀerenti-
ation [2–4]. Among other histone modiﬁcations, acetylation
is very important in nucleosome assembly and chromatin
folding. Acetylation favors an open chromatin structure by
interfering with the interactions between nucleosomes and
releasing the histone tails from the linker DNA. Chromatin
regions that are marked by lysine acetylation catalyzed by
Histone Acetyl-transferase (HATs) are generally actively
transcribed, whereas regions that are bound by Histone
Deacetylases (HDACs) bear deacetylated lysines and are
inactive [5]. Accordingly, HATs and HDACs reside in multi-
protein coactivatory or corepressory complexes, respectively.
HATs and HDACs may act either in a site-speciﬁc manner,
whentheyarerecruitedthroughbindingtosequence-speciﬁc
DNA binding activators or repressors, or in a broad manner
whereby they function across large genomic areas.
There are up to date 18 genes coding for histone (or ep-
silon lysine) deacetylases in the mammalian genomes. They
are grouped in four families. Group I (comprising HDACs 1,
2, 3, and 8). IIa (HDAC 4, 5, 7, 9), IIb (6, 10), III (SIRT 1–7),
a n dI V( H D A C1 1 )[ 6]. In spite of their name, histone
deacetylases have also nonhistone target proteins especially
those belonging to group II which do not have histones as
substrates. Class I HDACs participate in diverse repressory
complexes via interaction with diﬀerent cofactors such as the
Sin3A,Nurd,andCoRest[7].Contrarytotheirconsideration
asrepressors,HDACsmayactascoactivatorsoftranscription
as was reported in the interferon stimulated genes [8]. Ge-
nome-wide detection of HATs and HDACs of higher eukary-
otic organism has revealed a highly complex situation, active2 Stem Cells International
genes are bound by both enzyme types, whereas inactive
genes are not bound by HDACs [9]. Inactive genes that were
primed for activation by H3K4 methylation were transiently
b o u n db yb o t hH A T sa n dH D A C s[ 9].
HDAC inhibitors (HDACis) are natural or synthetic
small molecules that can inhibit the activities of HDACs. In
spite of similarities in their enzymatic activities, loss of func-
tionexperiments have attributedhighlyspeciﬁcrolesto indi-
vidual members of HDAC proteins in the course of devel-
opment and diﬀerentiation. In addition, HDAC inhibitors
that have broad speciﬁcity towards their HDAC targets have
shownhighlyspeciﬁceﬀectsdependingonthetargetcelltype
[10].
T h ep r o f o u n dev e n t st h a tg o v e rns t e mc e lld i ﬀerentiation
and somatic cell reprogramming to pluripotency are mainly
epigenetic [11]. HDACis are epigenetic modiﬁers that can
promote eﬃcient and temporally regulated control of gene
expression. This paper will discuss the role of HDACi in stem
cell pluripotency and diﬀerentiation as well as in the repro-
gramming of somatic cells into pluripotency.
2. The Role of HDACClass Iand
IIMembers inMammalianDevelopment
and Differentiation
Analysis of knockout mice lacking HDAC genes has revealed
their functions during mammalian development and diﬀer-
entiation [10]. HDAC1 gene deletion is embryonic lethal
due to cell proliferation and growth defects [12]. The same
proliferation defects were reported in HDAC1-null embry-
onic stem (ES) cells which overexpress the cell cycle inhi-
bitors p21 and p27 [13]. This analysis has revealed a dual
role for HDAC1 in both repression and activation of gene
transcription. Tissue-speciﬁc deletion of HDAC1 in mice did
not have signiﬁcant eﬀect due to functional redundancy with
HDAC2 [14]. However, deletion of HDAC2 was reported to
cause perinatal lethality in one publication [12], whereas it
resulted in a failure to reactivate fetal gene expression prog-
ramme under cardiac hypertrophic stress in another study
[15]. Regarding cardiac growth and development, one allele
of either HDAC1 or 2 is suﬃcient, whereas conditional
deletion of both HDAC1 and 2 is lethal due to heart develop-
ment failure [12].
Similar to the cardiac diﬀerentiation, HDAC1 and 2 have
essential but redundant roles in the diﬀerentiation of neu-
ronal precursors into neurons [12]. Deletion of both en-
zymes results in severe brain abnormalities and lethality at
postnatal day 7 [12]. The roles of individual HDACs 1, 2, and
3 have been assessed in the diﬀerentiation of cortical stem
cells using dominant negative mutants [16]. Speciﬁcally,
all three of them inhibit oligodentrocytic diﬀerentiation,
HDAC2 inhibits astrocytic, whereas HDAC1 is required for
neuronaldiﬀerentiation.Ontheotherhand,speciﬁcdeletion
of both HDAC1 and 2 in oligodendrocyte lineage cells
resulted in Wnt pathway activation, which in turn inhibited
oligodendrocytedevelopmentbyrepressingOlig2expression
[17]. In agreement with these data, ablation of both HDAC1
and 2 in Schwann cells caused severe myelination deﬁciency
due to NFkB deacetylation [18].
Finally, HDAC1 and 2 have important functions in he-
mopoiesis [19]. HDAC1 activity is required for erythroid,
whereas it blocks myeloid diﬀerentiation [20].
HDAC3 deletion is embryonic lethal due to deﬁcient gas-
trulation[21–23]thatisconnectedtofailureinDNAdamage
repair mechanisms [23]. Conditional tissue-speciﬁc dele-
tions of HDAC3 have pointed to an involvement in liver [22]
and heart [21] function.
Although class I HDACs are widely expressed, members
of the IIa group show tissue-restricted expression. HDAC4
regulates skeletogenesis and knockout mice die in the ﬁrst
weekafterbirthduetoexcessiveossiﬁcationofendochondral
cartilage which interferes with breathing [24]. This eﬀect
is due to unrestricted function of MEF2 and RUNX2, two
transcription factors that activate bone formation [25, 26].
RUNX2 is activated by MEF2 and both MEF2 and RUNX2
are targeted by HDAC4 [26]. HDACs 5 and 9 control, in
redundant manner, cardiovascular development since single
knockoutmiceareviable,whereasdoubledisruptionleadsto
lethality caused by defective cardiac development resulting
from unrestricted activation of MEF2- [27], SRF-, myo-
cardin- and Calmodulin-binding transcriptional activator 2
[28]. In addition, HDAC 4, 5, and 9 control skeletal muscle
diﬀerentiationthroughnegativeregulationofMEF2,PGC1a,
and NFAT in response to calcium signals [29]a n dm o t o r
neuron activation [30]. HDAC7 is speciﬁcally expressed
in endothelial cells of the cardiovascular system [31]a n d
HDAC7 gene deletion results in embryonic lethality due to
vascular rupture and excessive hemorrhages [31]. These ef-
fects are caused by extreme activation of matrix metallopro-
teinase (MMP) 10 which is normaly inhibited by HDAC7
[31]. Members of the HDAC class IIb group (HDAC 6, 10)
regulate cytoskeletal dynamics by controlling the acetylation
of cytoskeletal proteins such as tubulin [32].
HDAC expression and activity are intimately associated
with the emergence of neoplasias. In Acute Promyelocytic
Leukemia (APL), fusions between Promyelocytic Leukemia
(PML) and Retinoic Acid Receptor (RAR) recruit HDACs
resulting in the repression of diﬀerentiation-related genes
[33, 34]. In solid tumors, mutations in HATs [35]a n do v e r -
expression of HDAC-associated proteins lead to relative
hyperactivity of HDAC. Consequently, HDAC inhibitors are
long established antitumor agents that were known before
the identiﬁcation of their target HDAC molecules [34, 36].
3. Inhibitorsof HDACs
HDAC class I and II inhibitors (HDACi) fall into discrete
structural categories such as hydroxamic acids, cyclic pep-
tides, benzamides, benzofuranone, and sulfonamide con-
taining molecules [37, 38]. The biological eﬀects of HDACi
result from positive or negative regulation of gene expression
by induced acetylation of histones, transcription factors or
other proteins. Genome-wide analyses of gene expression
changes upon HDACi administration have revealed that
approximately equal numbers of genes are induced and
repressed [39]. The genes aﬀected are highly dependent on
the cell type and transformed cells are extremely sensitive as
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with transformed cells. The antitumor activity of HDACi
results from a combination of many processes involving cell
cycle arrest, apoptosis, activation of mitotic cell death, and
inhibition of angiogenesis. In addition, but not unrelated to
the aforementioned eﬀects on cell functions, HDACis were
reported to induce diﬀerentiation of certain cancer cell types
[36]. This property gains extreme importance in light of the
recently established discovery of “cancer stem cells” [40], a
smallpopulationofcellsthatareabletoreproducethetumor
and possess self-renewal and pluripotency activities.
4. HDACInhibitorsinStem Cell
Self-Renewal and Differentiation
Due to their activity in epigenetic regulation, HDACis have
been widely used in order to alter the diﬀerentiation state of
stem and somatic cells as shown in Table 1.
4.1. Embryonic Stem Cell Pluripotency. Diﬀerentiation is a
process of gradual loss of potency that ends up to the point
where speciﬁc cell fate is acquired. Embryonic stem (ES) cells
are isolated from the inner cell mass of blastocysts [1, 41, 42]
and are characterized by indeﬁnite self-renewal and pluri-
potency, the capability to follow all potential diﬀerentia-
tion pathways [43, 44]. Both mouse and human ES cells
express networks of pluripotency transcriptional regulators
exempliﬁed by Oct4, Sox2, and Nanog [45]. They diﬀer
in the requirements for externally provided cytokines and
growth factors. For instance, mouse ES cell culture requires
Leukemia Inhibiting Factor (LIF) [46], whereas human ES
cell culture depends on Activin/Nodal and FGF [47]. This
diﬀerence is due to the developmental stages from which
thesetwocelltypeswereisolated.HumanEScellsarederived
from later stage of embryonic development compared to the
mouse and are highly similar to mouse EpiSC (epiblast stem
cells) [47–49]. The diﬀerentiation of stem cells is very sensi-
tive to epigenetic changes. Therefore, application of epige-
netic regulators such as inhibitors of DNA methylation (5
Azacytidine) and HDAC inhibitors may be valuable tools for
stem cell interventions [50].
In accordance with their eﬀects on the diﬀerentiation of
cancer cells, HDACis are able to promote the diﬀerentiation
of ES cells. Treatment with Trichostatin A (TSA) promotes
morphological and gene expression changes reminiscent of
diﬀerentiationeveninthepresenceofLIF[51,52].Inhibition
ofHDACactivityacceleratedtheearlydiﬀerentiationstepsof
EScellswithoutbeingsuﬃcientforcommitmenttoaspeciﬁc
lineage.Genome-wideanalysisrevealedtwogenegroupsthat
are targeted by TSA: the ﬁrst one contains genes related to
pluripotency that are suppressed by TSA (Sall4, Nanog, Klf4,
Oct4, and Sox2), the second is required for lineage-speciﬁc
diﬀerentiation and its expression is upregulated by TSA [52].
Incontrasttothesestudies,otherstudieshaveshownthat
HDACis increase self-renewal and interfere with diﬀerentia-
tion. Low doses of TSA (10nM) reverted mouse embryoid
bodies towards the undiﬀerentiated state [53] and employ-
ment of sodium butyrate (NaBu) was reported to support
human and mouse ES cells self-renewal when administered
within a narrow range of concentrations [54]. In the latter
study,lowdosesofbutyrate(andTSA)wereabletosubstitute
for FGF2 (human ES) and LIF (mouse ES). However, higher
doses led to diﬀerentiation. Surprisingly, nonoverlapping
transcriptional expression proﬁle changes were observed in
butyrate-treatedhumanandmouseEScells[54].Theseﬁnd-
ings have shown the ability of butyrate to modulate the stem
cell stage pushing mouse ES forward and pulling human ES
backward [54]. In agreement with these data, treatment of
mouse ES with TSA was able to shift a population of epi-
blast-like ESC towards an ICM-like state [54, 55]. A conclu-
sion of all these studies might be that HDACis exert an anti-
diﬀerentiation eﬀect when low doses are applied on cells
that have already exited from self-renewal either as embryoid
bodies [53] or epiblast-like [54, 55] cells, whereas higher
doses applied on undiﬀerentiated cells provoke diﬀerentia-
tions [51, 52]. The same eﬀect was observed upon HDACi
treatmentoftwoembryoniccarcinoma(EC)celllinesF9and
P19. In F9 cells which belong to a less diﬀerentiated state,
the expression of the pluripotency factor Fgf4 decreased after
treatmentwithValproicacid(VPA)andTSA.Incontrast,the
same treatment of P19 cells, which are more diﬀerentiated,
caused the elevation of Fgf4 expression [56]. In agreement
with this data, reactivation of pluripotency genes such as
Oct4, Nanog, and Klf4 was observed in neurosphere cells
treatedwithTSAandazacytidine,AzaC[57].Hence,changes
in the acetylation levels of stem cells result in alterations of
thediﬀerentiationstatusincorrelationwiththedevelopmen-
tal stage.
Directed diﬀerentiation of ES cells is not easy to control.
Diﬀerentiation protocols generally rely either on the gen-
eration of ES cell aggregates (embryoid bodies) or on cul-
turing on stromal cells. Eﬀectiveness and selectivity need to
be signiﬁcantly improved in order for ES cell to be used as
tools for cell-based therapies.
HDACi treatment was used for directed diﬀerentiation
of mouse ES cells towards the cardiomyocytic lineage. TSA
added on embryoid bodies between days 7 and 8 potentiated
cardiac diﬀerentiation due to hyperacetylation of GATA4
[58] a master regulator of cardiogenesis. In addition, TSA
induced, whereas HDAC4 overexpression inhibited, car-
diomyogenesis of embryonic carcinoma P19 cells [59]. TSA
was also able to facilitate the myocardial diﬀerentiation of
induced pluripotent stem cells [60]. Interestingly, TSA and
NaBu were reported to induce HDAC4 proteasomal degra-
dation which in turn results in MEF2 activation and cardiac
lineage commitment [61]. On the other hand, NaBu was
proven eﬀective in the induction of pancreatic and hepatic
diﬀerentiation from mouse and human ES cells [62–64].
4.2. Tissue-Speciﬁc Stem Cells
4.2.1. Neural Stem Cell Diﬀerentiation. As indicated previ-
ously ablation of HDAC1 and 2 is postnatal lethal due to
disorganization of brain structures [12]. However, adminis-
tration of HDAC inhibitors led to the induction of neuronal
and suppression of glial diﬀerentiation [65]. In addition
HDAC activity is required for timing of oligodendrocyte
diﬀerentiation [66].4 Stem Cells International
Table 1: Functions of HDAC inhibitors in stem cell self-renewal or diﬀerentiation and somatic cell reprogramming to pluripotency.
Name Chemical structure Self-renewal Diﬀerentiation Reprogramming References
Apicidin
H O
O
O
O
O
O
H
NH
HN
HN
N
N
CH3
CH3
H3C
H3C
——+ [ 67]
m-Carboxycinnamic acid
bishydroxamide (CBHA)
O O
HO OH
N
H
N
H ——+ [ 68]
Chlamydocin
HN H
N
N
O
O
NH
O
O
O
O
↑ HSCs [69]
Entinostat (MS-275)
N
O
H
N
NH
O
O
NH2 —
↑ Neuronal
↓ Oligodentrocytic + [70]
[67]
M344
O
N
N
H
O
NH
OH —
↑ Neuronal
↓ Oligodendrocyte —[ 70]
Oxamﬂatin
OH N
H NH
S
O
O
O
——+ [ 71]
Scriptaid
O
OH
N
H
O
O
N ——+ [ 72]
Sodium butyrate
(NaBu)
H3C
CH3
O
O− Na+
↑ hESC
↑ mESC
[52]
[52]
↓ Adipogenic,
chondrogenic
neurogenic
↑ Osteogenic
↑ Ductal
↑ Pancreatic and
hepatic
[73]
[73]
[74]
[60–62]
+[ 67, 75, 76]
Suberoylanilide
hydroxamic acid
(SAHA)
O
OH
H
N
O
N
H
—
↑ Neuronal
↓ Oligodendrocyte [70]
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Table 1: Continued.
Name Chemical structure Self-renewal Diﬀerentiation Reprogramming References
Trichostatin A
(TSA)
OH
NH O
O
CH3
CH3
CH3
N
H3C
↑ mESC
↑ ECCs (P19)
↑ Neurosphere
cells
[51]
[54]
[55]
↑ ESCs
↑ NSCs
Ductal
Cardiomyocytic
↑ ECCs (F9)
↑ Myocardial
[49, 50]
[77]
[74]
[78]
[54]
[58]
+[ 67, 79–81]
Valproic acid
(VPA)
H3C CH3
O OH
↑ ECCs (P19) [54]
↓ Adipogenic,
chondrogenic
neurogenic
↑ Osteogenic
↑ Ductal
↑ ECCs (F9)
↓ Astrocyte,
oligodendrocyte
↑ Neuronal
[73]
[73]
[74]
[54]
[65]
[63, 66, 82]
+[ 81, 83]
Embryonic Stem Cells (ESCs), embryonic carcinoma Cells (ECCs), hemopoietic stem cells (HSCs), and neural stem cells (NSCs).
Speciﬁcally, VPA was reported to increase neuronal dif-
ferentiationofadultneuralprogenitorcellsandinhibitastro-
cyte and oligodendrocyte diﬀerentiation [65]. Moreover,
VPA administration inhibited the diﬀerentiation of oligo-
dendrocyte progenitor cells in the developing rat brain [66].
The molecular mechanism of VPA function was induc-
tion of NeuroD, a neurogenic bHLH transcription factor
[65]. Derepression of NeuroD and neuronal fate activation
wasalsocausedbyHDAC5nuclearexclusion[77].Inanother
study, VPA promoted neuronal fate commitment via acti-
vation of the ERK pathway [70]. TSA was able to increase
diﬀerentiation of neural stem cells at the expense of astrocyte
production [82]. Importantly, the TSA-produced nerve cells
bear normal electrophysiological properties and morpholog-
ical characteristics such as the extension of long dendrites
with branching points. Treatment of Adult Subventricular
Zone (SVZ) precursor cells with MS-275, M344, and sub-
eroylanilide hydroxamic acid (SAHA) increased neuronal
diﬀerentiation and inhibited oligodendrocyte production via
induction of NeuroD cyclinD2 and B-lymphocyte translo-
cation gene 3 [84] .V P Aw a sr e p o r t e dt op r o m o t en e u r o n a l
diﬀerentiation of hippocampal neural progenitor cells by
induction of proneural factors Ngn1, Mash1, and p15 and
histone H4 acetylation [85]. Combination of TSA with Shh,
Fgf8,andWnt1promotesdiﬀerentiationofnonmecencepha-
lic neural stem cells to dopaminergic neurons [69]. Interest-
ingly,theregulatoryroleofhistoneacetylationinthenervous
system is evolutionarily conserved between vertebrates and
invertebrates. High levels of acetylation are required for
neuronal, whereas low levels are connected to the glial dif-
ferentiation of Drosophila neural stem cells [86].
4.2.2.HemopoieticStemCellSelf-RenewalandDiﬀerentiation.
Mouse and human hemopoietic stem cells (HSC) self-
renewal was potentiated by chlamydocin [87]. In another
study, the application of TSA with 5-AzaC increased 12.5-
fold the proliferation of HSC isolated from umbilical cord
HDACi [73, 74].
Mesenchymal stem cells (MSCs) from adipose tissue and
umbilical cord blood were treated with two HDAC inhi-
b i t o r s ,V P A ,a n dN a B u[ 88]. Posttreatment controlled dif-
ferentiation was conducted into bone, fat, cartilage, and ner-
vous tissue. Diﬀerent results were obtained depending on the
cell types which were examined. VPA and NaBu attenuated
the eﬃciency of adipogenic, chondrogenic, and neurogenic
derivation.Ontheotherhand,osteogenicdiﬀerentiationwas
elevatedafterHDACi treatment.Aninterestingnewprospect
has arisen following a publication which supports that
HDAC inhibitors can be used to direct pancreatic cells to a
speciﬁc lineage. It was shown that NaBu and TSA promote
ductal diﬀerentiation at the expense of the acinar fate [78].
Thus,cellswithexocrinefunctionareconvertedtoendocrine
cells, capable of producing hormones such as insulin and
somatostatin [89].
4.2.3. Cardiomyocytic Diﬀerentiation. Cardiac side popula-
tion cells isolated from rat hearts were coaxed in cardiomy-
ocytic diﬀerentiation by TSA treatment [90]. TSA induced
the expression of transcription factors Nkx2.5, GATA4, and
MEF2C that play important roles in the orchestration of
the events that lead to the production of cardiomyocytes,
endothelial, and smooth muscle cells [90]. In another study,
TSA and azacytidine treatment promoted cardiomyocytic6 Stem Cells International
diﬀerentiation of mesenchymal stem cells via induction of
the same transcription factors GATA-4, NKx2.5, and MEF2c
[91].
5.HDACInhibitorsinCellReprogramming
to Pluripotency
Reprogramming diﬀerentiated somatic cells to pluripotent
stem cells has emerged as a way of producing patient-speciﬁc
stem cells. These cells can be possible candidates for regen-
erative medicine after their diﬀerentiation to a speciﬁc cell
fate.
A strategy used to reverse the diﬀerentiated state of cells
was somatic cell nucleus transfer (SCNT) to enucleated eggs
or oocytes [92, 93]. This proved in an emphatic way the fact
that cell diﬀerentiation is not an irreversible process and that
the nucleus of a diﬀerentiated cell can be reprogrammed to
follow a dediﬀerentiation program. Additionally, it is a com-
mon belief that the more ancestral a cell is, the easier it is
to be reprogrammed using the method of nuclear transfer.
There are several reports showing that HDAC inhibitors can
in fact be very helpful tools in the attempt to increase the
eﬃciency of nuclear transfer experiments (Table 1).
Early reports have applied TSA to donor cells [94]o r
to the embryos following SCNT [68, 72] and shown that it
improves both the in vivo and in vitro developmental rate.
TSA was eﬀective as cloning facilitating reagent for many
speciesembryos,bovine([95],mouse([71,96]),andporcine
([97]). TSA treatment caused chromatin rearrangements
suchaselevatedhistone acetylationandchromosomedecon-
densation as well as increased rate of RNA synthesis [98]).
TreatmentofSCNT-generatedmouseembryoswithscriptaid
improved the cloning eﬃciency for various inbred strains
[96]. Moreover, scriptaid treatment resulted in higher levels
of nascent mRNA transcription at the two-cell stage and this
increase depended on the genotype of the mouse strain used.
The cloned mice were both viable and fertile and there was
a positive correlation between the increase in nascent mRNA
synthesis and full-term development of cloned mice [96]. A
diﬀerent HDACi, CBHA, was reported to augment the devel-
opmental potential of cloned mouse embryos at both the
pre-andpostimplantationstages.Furthermore,CBHAtreat-
ment resulted in a statistically signiﬁcant increase in the
total ICM cell number, simultaneously reducing the ratio
of apoptotic cells. In addition, it was shown that Oct4 ex-
pression was more abundant in the population of cells iso-
latedfromblastocystsoftreatedanimalsthanuntreatedones.
Hence, those cells resembled ES cells as was conﬁrmed by
staining for pluripotency markers (Sox2, SSEA1, alkaline
phosphatase) [71]. Finally two other HDAC I and IIa/b
inhibitors suberoylanilide hydroxamic acid (SAHA) and ox-
amﬂatin could improve the development of cloned mice by
reducing the apoptosis in blastocysts [99].
In a pioneer work, the group of Yamanaka [100]r e p r o -
grammed fetal and adult mouse ﬁbroblasts to induced Plu-
ripotent Stem (iPS) cells using four key transcription factors,
namely Oct4, Sox2, c-Myc, and Klf4. A year later human ﬁ-
broblasts were reprogrammed by the group of Takahasi et al.
[101]a n dP a r ke ta l .[ 79], whereas the group of Thomson
substitutedtheoncogenicfactorsKlf4andc-MycwithNanog
and Lin28 [102]. The aforementioned iPS cells possess iden-
tical characteristics with ES cells, such as expression of pluri-
potency markers, ES cell morphology, self-renewal, and
capability of teratoma formation [79, 101].
In order to improve the eﬃciency of reprogramming,
s e v e r a ls t r a t e g i e sw e r ed e v e l o p e d[ 83] using small molecules
such as DNA methyltransferase inhibitors (5 AzaC, [75]),
histone methylotransferase inhibitors (BIX, [76]), and
HDAC inhibitors (Table 1). Important steps have been made
towards the direction of replacing the oncogenic factors with
chemical compounds. In particular, Valproic acid (VPA)
was used to substitute for c-myc [80]. VPA and the pluri-
potency factors Oct4, Sox2, and Klf4 were able to reprogram
primary human ﬁbroblasts. The presence of VPA increased
the number of iPS colonies by 50-fold. Produced iPS cells
resemble ES cells in pluripotency and gene expression
proﬁles [80]. In another study, Klf4 was fully dispensable
[67]. The combination of Oct4, Sox2, and VPA was suﬃcient
toreprogramsomaticcellswithasimilareﬃciencycompared
tothree-factorreprogramming(Oct4,Sox2,andKlf4).These
iPS cells exhibited several desired characteristics, such as
increased levels of pluripotency markers and alkaline phos-
phatase activity. In addition, they seemed morphologically
similar to human ES cells and were karyotypically normal.
Finally, the two factor-induced human iPS cells were able to
form teratomas derived from all three lineages. It is possible
that VPA treatment sets somatic cells in a transition state
before their complete dediﬀerentiation [67]. These results
oﬀer great possibilities in attaining full reprogramming with
chemical reagents, a procedure both safe and practical to be
used in human therapies.
In a recent study [75], human fetal ﬁbroblasts were re-
programmed to pluripotency using human ES cell extracts
with the addition of 5-azacytidine, TSA, and retinoic acid.
Thisprovesthattheepigeneticstateofcellshasagreatimpact
on the eﬃciency of reprogramming by this method. During
the process, upregulation of pluripotency markers (Oct4,
Sox2) and morphological changes were observed. In parallel,
markers of diﬀerentiation (LAMIN A/C) were downregu-
lated, showing a positive correlation between dediﬀerentia-
tion, and increase in acetylation status of cells.
Another HDAC inhibitor NaBu used at low doses im-
proved the generation of iPS cells by 50-fold by using retro-
viral or “piggyback” vectors for reprogramming human ﬁ-
broblasts even in the absence of Klf4 and c-myc [81]. In
another study, butyrate was reported to potentiate iPS cell
generation from mouse embryonic ﬁbroblasts in the pres-
ence of c-myc [103]. This diﬀerence might be due to dif-
ferences in the endogenous c-myc levels between the human
and mouse cells.
In addition to the typical iPS cells, reversion of diﬀeren-
tiation was assisted by the addition of HDACi in other cell
types. Dediﬀerentiation of primordial germ cells (PGC) into
pluripotent embryonic germ (EG) cells was achieved using
TSA to replace FGF-2 [104]. A high-throughput screen has
revealed the ability of four HDAC inhibitors (NaBu, TSA,
MS-275 and Apicidin) to reprogram oligodendrocyte pro-
genitors (OPC) into multipotent neural stem-like cells thatStem Cells International 7
can generate both neurons and glia [105]. Finally, an intrigu-
ing new possibility emerged from a recent publication using
the nematode C. elegans as model [106]. The researchers
employed two common HDAC inhibitors (VPA and TSA)
to mimic the removal of histone chaperone LIN-53 and
managed to reprogram germ cells into speciﬁc neuron types.
It would be interesting to examine the eﬀect of HDAC inhi-
bition in eﬀorts of direct reprogramming from one type to
the other in the more complex context of mammalian cells.
6. Conclusions andPerspectives
Stem cell methodologies have revolutionized modern thera-
peutic strategies that aim to replace damaged cells or tissues.
Controlling the pluripotent stem cell fate [95]i sd e p e n d e n t
onimportanttranscription,signaling,andepigeneticfactors.
Among other epigenetic regulators, Histone deacetylases
have important roles in cell physiology, diﬀerentiation,
developmental decisions, and tumor formation [10]. Com-
pared to HDAC genes deletions, HDAC inhibitors elicit cell
restricted, albeit pleiotropic eﬀects. A vast collection of nat-
ural and synthetic HDAC inhibitors has shown very potent
eﬀects in embryonic stem cell diﬀerentiation pathways. They
may promote either self-renewal [54, 55]o rd i ﬀerentiation
[51, 52] depending on the stem cell status and the dose
employed. These eﬀects might result from reorganization of
the embryonic stem cell chromatin that is remarkably dyna-
mic and decondensed [107]. Therefore, HDACi can reverse
the repressive or activating epigenetic traits that characterize
genes involved in the regulation of self-renewal or diﬀerenti-
ation.
Most importantly, HDACis have shown considerable
activity in directing the neuronal, cardiomyocytic, and hep-
atic lineages diﬀerentiations. In most cases where the molec-
ular mechanism was examined, it involved the induction
of diﬀerentiation-regulating transcription factors. Moreover,
HDACis were used in somatic cell reprogramming processes.
Treatment of donor cells before transfer or embryos fol-
lowing transfer resulted in facilitation of embryo cloning
and improvement of embryo developmental potential. These
eﬀects were due to enhanced histone acetylation, chromatin
decompaction, increase of RNA synthesis, and inhibition of
apoptosis.Duetotheethicalissuesraisedbyembryocloning,
thesetechniquesarenotyetapplicabletohumans.Therefore,
the recent achievement of iPS generation has oﬀered great
expectations in custom-speciﬁc stem cells for human health.
In that ﬁeld, there is increasing eﬀort in omitting retroviral
vectors, oncogenes, and—if possible—all kinds of exogenous
genetic material. Substituting transcription or signaling fac-
tors with simple small molecule reagents can render the ther-
apies both safer and simpler. For that purpose, HDAC inhi-
bitors have shown activity to enhance reprogramming and
substitute for the presence of transcription factors, impor-
tantly the oncogenes c-myc and Klf4 [67]. However, the
exact molecular mechanism whereby VPA, TSA, and other
HDACi function needs to be elucidated. Future researches
are expected to elucidate the mechanism of HDACi action
in order to design novel reagents with increased eﬀectiveness
and speciﬁcity. On the other hand, genome-wide analyses
have shown that acetylation is a modiﬁcation as frequent as
phosphorylation. Considering that nonhistone proteins are
also targets for acetylation, it is expected that analysis of the
“acetylome” [108, 109] changes in the course of stem cell dif-
ferentiation will shed light on the functions and applications
of HDAC inhibitors. In addition to mRNA proﬁling, analysis
of miRNA expression changes that follow HDACi may reveal
mechanisms whereby these reagents have so speciﬁc eﬀects
on diﬀerent cell diﬀerentiation backgrounds. HDACis are
able to potentiate both stem cell diﬀerentiation and somatic
cell reprogramming to pluripotency. This may suggest that
common mechanisms are involved in opposite changes of
the diﬀerentiation status. Elucidation of these mechanisms is
expected to open new opportunities in the interface between
chemistry and stem cell biology. Combining HDAC inhi-
bitors with other small molecule eﬀectorsand miRNAs [110]
can provide valuable tools to overcome challenges due to
genetic interventions and improve stem cell applications for
tissue regeneration therapies.
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